BMY registry changes
Status changes, moved primary completion and completion dates, and results first posted on ClinicalTrials.gov, for trials linked to listed companies. Newest detection first.
Newest change detected Nov 19, 2026, 8:47 AM ET
| Detected | Trial | Change | Now | Before | Record updated |
|---|---|---|---|---|---|
| Nov 19, 2026, 8:47 AM ET | Completion date | Sep 28, 2026 (actual) | Locked | Locked | |
| Nov 19, 2026, 8:47 AM ET | Primary completion date | Sep 28, 2026 (actual) | Locked | Locked | |
| Nov 19, 2026, 8:47 AM ET | Status | Completed | Locked | Locked | |
| Nov 18, 2026, 9:47 AM ET | Status | Recruiting | Locked | Locked | |
| Nov 17, 2026, 9:52 AM ET | Completion date | Apr 1, 2027 (sponsor estimate) | Locked | Locked | |
| Nov 16, 2026, 8:47 AM ET | Completion date | Sep 2, 2026 (actual) | Locked | Locked | |
| Nov 16, 2026, 8:47 AM ET | Status | Completed | Locked | Locked | |
| Nov 12, 2026, 8:11 AM ET | Completion date | Dec 15, 2030 (sponsor estimate) | Locked | Locked | |
| Nov 12, 2026, 8:11 AM ET | Primary completion date | Dec 15, 2030 (sponsor estimate) | Locked | Locked | |
| Nov 12, 2026, 8:11 AM ET | Status | Active, not recruiting | Locked | Locked | |
| Nov 12, 2026, 8:11 AM ET | Completion date | Oct 16, 2026 (actual) | Locked | Locked | |
| Nov 12, 2026, 8:11 AM ET | Status | Completed | Locked | Locked |
- Detected Nov 19, 2026, 8:47 AM ETCompletion dateNCT07204418A Study to Evaluate the Effects of CYP2D6 Phenotypes on the Pharmacokinetics of Xanomeline Following KarXT Administration in Healthy...BMY
- Now
- Sep 28, 2026 (actual)
- Before
- Locked
- Detected Nov 19, 2026, 8:47 AM ETPrimary completion dateNCT07204418A Study to Evaluate the Effects of CYP2D6 Phenotypes on the Pharmacokinetics of Xanomeline Following KarXT Administration in Healthy...BMY
- Now
- Sep 28, 2026 (actual)
- Before
- Locked
- Detected Nov 19, 2026, 8:47 AM ETStatusNCT07204418A Study to Evaluate the Effects of CYP2D6 Phenotypes on the Pharmacokinetics of Xanomeline Following KarXT Administration in Healthy...BMY
- Now
- Completed
- Before
- Locked
- Detected Nov 18, 2026, 9:47 AM ETStatus
- Now
- Recruiting
- Before
- Locked
- Detected Nov 17, 2026, 9:52 AM ETCompletion dateNCT02648997An Open-Label Phase II Study of Nivolumab or Nivolumab/Ipilimumab in Adult Participants With Progessive/ Recurrent MeningiomaBMY
- Now
- Apr 1, 2027 (sponsor estimate)
- Before
- Locked
- Detected Nov 16, 2026, 8:47 AM ETCompletion dateNCT02989636Nivolumab With or Without Stereotactic Radiosurgery in Treating Patients With Recurrent, Advanced, or Metastatic ChordomaBMY
- Now
- Sep 2, 2026 (actual)
- Before
- Locked
- Detected Nov 16, 2026, 8:47 AM ETStatusNCT02989636Nivolumab With or Without Stereotactic Radiosurgery in Treating Patients With Recurrent, Advanced, or Metastatic ChordomaBMY
- Now
- Completed
- Before
- Locked
- Detected Nov 12, 2026, 8:11 AM ETCompletion dateNCT04159818Immune Induction Strategies to Improve Response to Immune Checkpoint Blockade in Triple Negative Breast Cancer (TNBC) PatientsBMY
- Now
- Dec 15, 2030 (sponsor estimate)
- Before
- Locked
- Detected Nov 12, 2026, 8:11 AM ETPrimary completion dateNCT04159818Immune Induction Strategies to Improve Response to Immune Checkpoint Blockade in Triple Negative Breast Cancer (TNBC) PatientsBMY
- Now
- Dec 15, 2030 (sponsor estimate)
- Before
- Locked
- Detected Nov 12, 2026, 8:11 AM ETStatusNCT04159818Immune Induction Strategies to Improve Response to Immune Checkpoint Blockade in Triple Negative Breast Cancer (TNBC) PatientsBMY
- Now
- Active, not recruiting
- Before
- Locked
- Detected Nov 12, 2026, 8:11 AM ETCompletion dateNCT04446650A Study of Fedratinib in Japanese Subjects With DIPSS (Dynamic International Prognostic Scoring System)- Intermediate or High-risk...BMY
- Now
- Oct 16, 2026 (actual)
- Before
- Locked
- Detected Nov 12, 2026, 8:11 AM ETStatusNCT04446650A Study of Fedratinib in Japanese Subjects With DIPSS (Dynamic International Prognostic Scoring System)- Intermediate or High-risk...BMY
- Now
- Completed
- Before
- Locked
The previous value and the sponsor's record update date are locked on 12 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerTracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.
What is on this list
Changes Signal8 recorded between two refreshes of a trial's ClinicalTrials.gov record: status, primary completion and completion dates, and results first posted. A change is shown when it was detected, which can be days after the sponsor updated the record. Nothing here describes what a trial showed.
New registrations, enrollment, eligibility and outcome-measure edits are not recorded. A status change is the registry's own word for where the trial stands, and "results posted" means results were posted to the registry, never what they show.
Free readers see the first 25 changes of any filter with the new value. The previous value, the sponsor's record update date and later pages are part of the plan. See the methodology.